FORT MYERS, Fla.– NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions, announced that the U.S. District Court for the Middle District of North Carolina has granted its motion for summary judgment in a patent infringement lawsuit brought by Natera. The Court ruled that all of Natera’s asserted patent claims are invalid for claiming ineligible subject matter, dismissed Natera’s claims against NeoGenomics with prejudice, and entered declaratory judgment of invalidity for both patents.
The ruling clears the way for NeoGenomics to continue making, marketing, and selling its RaDaR ST molecular residual disease (MRD) assay in the United States. The test, formerly known as RaDaR 1.1, has already been launched to biopharma customers and submitted to the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) for clinical reimbursement coverage.
“We are pleased with the Court’s decision to invalidate Natera’s asserted patents,” said Tony Zook, CEO of NeoGenomics. “NeoGenomics is committed to providing cancer patients with the most comprehensive diagnostic testing options to enable the highest quality of personalized care, including MRD testing. We will continue to vigorously protect and defend our intellectual property to fuel the next wave of innovation and serve our patients.”
